Multiple Myeloma | Oncology Today with Dr Neil Love: Emerging Role of CELMoDs (Cereblon E3 Ligase Modulators) and Other Novel Approaches to Targeting Protein Degradation Pathways in Multiple Myeloma

Featuring an interview with Dr Paul G Richardson, including the following topics: Biologic rationale for targeting protein degradation pathways as a therapeutic approach in multiple myeloma (MM); mechanism of action of CELMoDs (0:00) Similarities and differences between iberdomide, mezigdomide and standard immunomodulatory drugs (7:14) Compassionate use of melflufen and belantamab mafodotin (12:08) Current management strategies for newly diagnosed MM (16:30) DETERMINATION: Evaluation of trial findings on racial and ethnic disparities and differential outcomes (23:02) Tailoring of up-front daratumumab-based therapies; management of extramedullary disease (33:17) CME information and select publications